Drug intelligence / Profile preview

berberine hydrochloride + probiotics

Development stage: Unknown
Lead developer: The Affiliated Hospital of Xuzhou Medical University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Berberine hydrochloride + probiotics is a combination therapy being investigated for the treatment of irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). Berberine hydrochloride is a plant-derived isoquinoline alkaloid with significant antimicrobial properties, particularly against pathogenic gut bacteria, and anti-inflammatory effects. The probiotic component, specifically Bifidobacterium tetravaccine (Live) Tablets in clinical studies by the Affiliated Hospital of Xuzhou Medical University, consists of *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. This combination aims to eradicate bacterial overgrowth in the small intestine while simultaneously restoring a healthy balance of commensal microbiota and strengthening the intestinal mucosal barrier.

Other names: berberine hydrochloride and probioticsberberine hydrochloride + Bifidobacterium tetravaccine

Beyond the preview

Go deeper on berberine hydrochloride + probiotics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on berberine hydrochloride + probiotics.

Explore the full profile